acquired coagulopathy
Conditions
Interventions
Rituximab
Sponsors
Gunma University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The patients who had a diagnosis of a hemorrhagic acquired coagulation disorder Age at agreement acquisition is the patients 85 years or younger 20 years old or older. About participation in this study, a document agreement is the obtained patients from person . (4) The patients who meet criteria of the following rituximab administration. (1) Recurrence, the intractable case that is refractory to steroid therapy (2) The patients that attending physitian judged that steroid use was not suitable for some reason by initial treatment. The steroid unsuitable corresponds to following a) The patients that exacerbation is expected with mental cognitive impairment. b) The patients who had the diabetes mellitus inadequate control. c) The patients who have hemorrhagic gastric ulcer. d) In addition, the patients that attending physitian judged steroid use to be inadequate.
Exclusion criteria
Exclusion criteria: (1) The men that an agreement is not obtained in preventing conception during study drug dosing period. (2) The women who may be pregnant during nursing during pregnancy and the women who hope for pregnancy during study drug dosing period. (3) The patients who are proved to have an HIV antibody. (4) The patients that positive was confirmed in one or more with HBs antigen, HBs antibody, anti-hepatitis B core antigen and HCV antibody. (however, we do not do it with the subject of the exclusion by this rule when a thing with the vaccination is clear when an examination of hepatitis B is positive) (5) In addition, the patients whom doctor attending judged to be inadequate as an object of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disappearance of coagulation factor inhibitor on day 56 after rituximab administration | — |
Countries
Japan
Contacts
Public ContactOgawa, Yoshiyuki
Gunma Unviersity School of Medicine
Outcome results
None listed